Literature DB >> 29166838

Immunohistochemical localization of nerve growth factor, tropomyosin receptor kinase A, and p75 in the bone and articular cartilage of the mouse femur.

Stephane R Chartier1, Stefanie At Mitchell1, Lisa A Majuta1, Patrick W Mantyh1,2.   

Abstract

Sequestration of nerve growth factor (NGF) significantly attenuates skeletal pain in both animals and humans. However, relatively little is known about the specific cell types that express NGF or its cognate receptors tropomyosin receptor kinase A (TrkA) and p75 in the intact bone and articular cartilage. In the present study, antibodies raised against NGF, TrkA, and p75 (also known as CD271) were used to explore the expression of these antigens in the non-decalcified young mouse femur. In general, all three antigens displayed a remarkably restricted expression in bone and cartilage with less than 2% of all DAPI+ cells in the femur displaying expression of any one of the three antigens. Robust NGF immunoreactivity was found in mostly CD-31- blood vessel-associated cells, a small subset of CD-31+ endothelial cells, an unidentified group of cells located at the subchondral bone/articular cartilage interface, and a few isolated, single cells in the bone marrow. In contrast, p75 and TrkA were almost exclusively expressed by nerve fibers located nearby NGF+ blood vessels. The only non-neuronal expression of either p75 or TrkA in the femur was the expression of p75 by a subset of cells located in the deep and middle zone of the articular cartilage. Understanding the factors that tightly regulate the basal level of expression in normal bone and how the expression of NGF, TrkA, and p75 change in injury, disease, and aging may provide insights into novel therapies that can reduce skeletal pain and improve skeletal health.

Entities:  

Keywords:  Decalcification; aging; pain; sensory; skeleton; sympathetic

Mesh:

Substances:

Year:  2017        PMID: 29166838      PMCID: PMC5724636          DOI: 10.1177/1744806917745465

Source DB:  PubMed          Journal:  Mol Pain        ISSN: 1744-8069            Impact factor:   3.395


  70 in total

1.  Efficacy, Safety, and Tolerability of Fulranumab as an Adjunctive Therapy in Patients With Inadequately Controlled, Moderate-to-Severe Chronic Low Back Pain: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Dose-loading Phase II Study.

Authors:  Panna Sanga; Elena Polverejan; Steven Wang; Kathleen M Kelly; John Thipphawong
Journal:  Clin Ther       Date:  2016-04-18       Impact factor: 3.393

2.  Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies.

Authors:  M C Hochberg
Journal:  Osteoarthritis Cartilage       Date:  2015-01       Impact factor: 6.576

3.  Noradrenergic and peptidergic innervation of the mouse femur bone marrow.

Authors:  Z Tabarowski; K Gibson-Berry; S Y Felten
Journal:  Acta Histochem       Date:  1996-11       Impact factor: 2.479

4.  Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis.

Authors:  David L Shelton; Jörg Zeller; Wei-Hsien Ho; Jaume Pons; Arnon Rosenthal
Journal:  Pain       Date:  2005-07       Impact factor: 6.961

5.  Antagonism of nerve growth factor-TrkA signaling and the relief of pain.

Authors:  Patrick W Mantyh; Martin Koltzenburg; Lorne M Mendell; Leslie Tive; David L Shelton
Journal:  Anesthesiology       Date:  2011-07       Impact factor: 7.892

6.  Expression patterns of neurotrophins and neurotrophin receptors in articular chondrocytes and inflammatory infiltrates in knee joint arthritis.

Authors:  Ola Grimsholm; Yongzhi Guo; Tor Ny; Sture Forsgren
Journal:  Cells Tissues Organs       Date:  2008-03-19       Impact factor: 2.481

7.  Sclerostin Immunoreactivity Increases in Cortical Bone Osteocytes and Decreases in Articular Cartilage Chondrocytes in Aging Mice.

Authors:  Michelle L Thompson; Juan Miguel Jimenez-Andrade; Patrick W Mantyh
Journal:  J Histochem Cytochem       Date:  2015-12-23       Impact factor: 2.479

8.  Exuberant sprouting of sensory and sympathetic nerve fibers in nonhealed bone fractures and the generation and maintenance of chronic skeletal pain.

Authors:  Stephane R Chartier; Michelle L Thompson; Geraldine Longo; Michelle N Fealk; Lisa A Majuta; Patrick W Mantyh
Journal:  Pain       Date:  2014-09-06       Impact factor: 6.961

9.  Proinflammatory cytokines stimulate the expression of nerve growth factor by human intervertebral disc cells.

Authors:  Yumiko Abe; Koji Akeda; Howard S An; Yasuchika Aoki; Rajeswari Pichika; Carol Muehleman; Tomoatsu Kimura; Koichi Masuda
Journal:  Spine (Phila Pa 1976)       Date:  2007-03-15       Impact factor: 3.468

10.  Scientometrics of drug discovery efforts: pain-related molecular targets.

Authors:  Igor Kissin
Journal:  Drug Des Devel Ther       Date:  2015-07-01       Impact factor: 4.162

View more
  8 in total

Review 1.  Targeting neurotrophic factors: Novel approaches to musculoskeletal pain.

Authors:  Anne-Marie Malfait; Rachel E Miller; Joel A Block
Journal:  Pharmacol Ther       Date:  2020-04-18       Impact factor: 12.310

Review 2.  The evolution of nerve growth factor inhibition in clinical medicine.

Authors:  Barton L Wise; Matthias F Seidel; Nancy E Lane
Journal:  Nat Rev Rheumatol       Date:  2020-11-20       Impact factor: 20.543

3.  Involvement of Oxidative Stress and Nerve Growth Factor in Behavioral and Biochemical Deficits of Experimentally Induced Musculoskeletal Pain in Mice: Ameliorative Effects of Heraclin.

Authors:  Anudeep Kaur; Lovedeep Singh; Saweta Garg; Harmanpreet Kaur; Nirmal Singh; Rajbir Bhatti
Journal:  J Mol Neurosci       Date:  2020-07-16       Impact factor: 3.444

4.  Anti-nerve growth factor does not change physical activity in normal young or aging mice but does increase activity in mice with skeletal pain.

Authors:  Lisa A Majuta; Stefanie A T Mitchell; Michael A Kuskowski; Patrick W Mantyh
Journal:  Pain       Date:  2018-11       Impact factor: 7.926

Review 5.  Nerves in Bone: Evolving Concepts in Pain and Anabolism.

Authors:  Jennifer M Brazill; Alec T Beeve; Clarissa S Craft; Jason J Ivanusic; Erica L Scheller
Journal:  J Bone Miner Res       Date:  2019-07-26       Impact factor: 6.741

Review 6.  Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety.

Authors:  Martin Schmelz; Patrick Mantyh; Anne-Marie Malfait; John Farrar; Tony Yaksh; Leslie Tive; Lars Viktrup
Journal:  Pain       Date:  2019-10       Impact factor: 7.926

7.  Osteoporosis in Light of a New Mechanism Theory of Delayed Onset Muscle Soreness and Non-Contact Anterior Cruciate Ligament Injury.

Authors:  Balázs Sonkodi; Rita Bardoni; Gyula Poór
Journal:  Int J Mol Sci       Date:  2022-08-12       Impact factor: 6.208

Review 8.  The Mechanism of Action between Pulsed Radiofrequency and Orthobiologics: Is There a Synergistic Effect?

Authors:  Daniel de Moraes Ferreira Jorge; Stephany Cares Huber; Bruno Lima Rodrigues; Lucas Furtado Da Fonseca; Gabriel Ohana Marques Azzini; Carlos Amilcar Parada; Christian Paulus-Romero; José Fábio Santos Duarte Lana
Journal:  Int J Mol Sci       Date:  2022-10-03       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.